All change in the prostate cancer diagnostic pathway

Area of Science:

• Urology
• Oncology
• Medical Imaging

Background:

• Current prostate cancer diagnosis relies on serum prostate-specific antigen (PSA) levels, leading to transrectal ultrasound-guided biopsies.
• This traditional method is inaccurate, risks sepsis, and often detects clinically insignificant cancers, causing overdiagnosis and unnecessary treatments.

Purpose of the Study:

• To describe the limitations of the current prostate cancer diagnostic pathway.
• To discuss the potential of advanced diagnostic tools like multiparametric MRI and novel tumor markers.
• To explore the impact of these innovations on risk stratification and future challenges.

Main Methods:

• Review of the current prostate cancer diagnostic pathway.
• Discussion of the utility of prebiopsy multiparametric MRI (mpMRI).
• Analysis of novel tumor markers and their role in diagnosis.

Main Results:

• Nontargeted biopsies are associated with significant inaccuracies and overdiagnosis of indolent prostate cancer.
• Multiparametric MRI and novel tumor markers offer improved accuracy in detecting clinically significant prostate cancer.
• These advancements have the potential to revolutionize prostate cancer diagnosis and risk stratification.

Conclusions:

• The current reliance on nontargeted prostate biopsies should be phased out due to its limitations.
• Integrating advanced imaging (mpMRI) and biomarkers into a new diagnostic pathway is crucial for accurate prostate cancer detection and management.
• Future challenges include refining risk-stratification systems and ensuring seamless adoption of new diagnostic technologies.